Articles

Published on 04 November 2014

2014/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2014, Issue 3 Editorial Regional regulatory processes for the approval of biosimilars; differences and similarities Original Research Barriers to market uptake of...

3.352 views

Read more →

Published on 05 January 2016

2015/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s fourth volume Commentary Bioequivalence of narrow therapeutic index drugs and immunosuppressives Original Research Prescribing practices for biosimilars: questionnaire survey findings...

3.068 views

Read more →

Published on 19 June 2015

2015/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2015, Issue 2 Commentary Pro-generics policies and the backlog in medicines registration in South Africa: implications for access to essential and affordable medicines Original...

3.181 views

Read more →

Published on 28 January 2019

2018/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s seventh volume Editorial Nomenclature for biosimilars; a continuing thorny issue Original Research Ongoing activities to influence the prescribing of proton...

2.542 views

Read more →

Published on 09 July 2020

2020/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2020, Issue 2 Commentary Importance of the determination of the higher order structure in the in-use stability studies of...

2.075 views

Read more →

Published on 21 June 2017

2017/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2017, Issue 2 Editorial Trends and challenges in biosimilars pricing and reimbursement policies in Europe and beyond Commentary Strategies...

2.499 views

Read more →

Regulatory

Published on 25 March 2020

Regulatory pathway for approval of ‘biosimilars’ in Iran

Abstract: Iran was the first country in the MENA (Middle East and North Africa) region to publish a legal framework for the registration of biosimilars. This framework is defined by...

Author(s): Jalal Naeli, MD

biopharmaceuticals, Iran, reference medicinal product

2.605 views

Read more →

Published on 09 March 2021

2021/1 GaBI Journal Table of Contents

Contents Editor’s Letter First 2021 GaBI Journal issue highlights Original Research Biosimilars – status in July 2020 in 16 countries An assessment of trends in the Iranian pharmaceutical market following...

1.759 views

Read more →

Published on 29 January 2015

2014/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s third volume Editorial Availability and procurement of generics in hospitals among medium-sized European countries Letters to the Editor Access to...

3.457 views

Read more →

Published on 01 January 2018

2017/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s sixth volume Letters to the Editor Clear naming, traceability of biological medicines will protect patients Comment on the non-biological complex...

2.984 views

Read more →

Published on 29 September 2021

2021/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2021, Issue 3 Original Research Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers Reasons for patients’ generic drug switching at the...

1.609 views

Read more →

Thank you to reviewers

Published on 03 January 2023

2022/3 GaBI Journal Table of Contents

Contents Editor’s Letter The importance of trust Original Research Social trust and regional variation in the adoption of biosimilars in Italy and Germany US prescribers’ attitudes and perceptions about biosimilars Review...

1.128 views

Read more →